{"brief_title": "Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder", "brief_summary": "This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot. Key objectives of the study are to: - Determine how well intramuscular (IM) olanzapine depot works during long-term treatment, - Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment, - Determine the blood levels of IM olanzapine depot in patients during long-term treatment", "condition": ["Schizophrenic Disorders", "Schizoaffective Disorder"], "intervention_type": ["Drug"], "intervention_name": ["Intramuscular olanzapine depot"], "description": ["45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval."], "arm_group_label": ["Intramuscular Olanzapine Depot"], "other_name": ["LY170053", "Zyprexa Adhera"], "criteria": "Inclusion Criteria: - Patients must have schizophrenia - Female patients of childbearing potential must be using a medically accepted means of contraception - Patients must have completed (within 10 days) another IM olanzapine depot study if permitted by that study's protocol. Exclusion Criteria: - Patients must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry - Female patients must not be pregnant or breast-feeding - Patients must not be experiencing acute, serious or unstable medical conditions other than schizophrenia or schizoaffective disorder - Patients must not have a substance (except nicotine or caffeine) dependence within the past 30 days", "gender": "All", "minimum_age": "18 Years", "maximum_age": "76 Years", "healthy_volunteers": "No", "mesh_term": ["Disease", "Schizophrenia", "Psychotic Disorders", "Olanzapine"], "id": "NCT00088465"}